Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, strengthened its leadership in mass spectrometry by launching new technologies to advance cutting-edge research and improve results in applied markets during the 65th Annual American Society for Mass Spectrometry (ASMS) Conference. Visitors can learn about the company’s latest technologies in Booth 601 at... Read more
BERWYN, Pa., June 5, 2017 /PRNewswire/ — After 27 years with AMETEK, Inc. (NYSE: AME), Frank S. Hermance has chosen to retire as Executive Chairman of the Board of Directors, effective July 7, 2017. Mr. Hermance’s retirement culminates a remarkable and distinguished career at AMETEK, including 17 years as Chief Executive Officer. Mr. Hermance, who joined... Read more
AUSTIN, Texas, June 5, 2017 /PRNewswire/ –Luminex Corporation (NASDAQ: LMNX) today announced that Japan’s Central Social Insurance Medical Council has approved the recommendation by the Japanese Ministry of Health, Labor and Welfare (MHLW) to provide reimbursement for two VERIGENE® assays: the Gram-Positive Blood Culture (BC-GP) test and the Gram-Negative Blood Culture (BC-GN) test. The MHLW established reimbursement went into... Read more
Basel, 05 June 2017 Phase III study showed Roche’s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer Second positive phase III head-to-head study to show Alecensa was superior to crizotinib in people with ALK-positive lung cancer Alecensa... Read more
Basel, 05 June 2017 Phase III study showed Roche’s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer Second positive phase III head-to-head study to show Alecensa was superior to crizotinib in people with ALK-positive lung cancer Alecensa... Read more
Basel, 05 June 2017 APHINITY study shows Roche’s Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer Phase III study confirms benefit of the Perjeta-based regimen over the current standard of care The study was positive in the overall population, with greatest risk reduction in... Read more
INDIANAPOLIS, June 5, 2017 /PRNewswire/ — Bruker is show-casing several new and innovative, high-performance mass spectrometry solutions for metabolomics, proteoform profiling and toxicology at ASMS 2017 (www.asms.org). Bruker is also celebrating 25 years of MALDI innovation with an emphasis on robust, high-throughput MALDI analytical, clinical and imaging solutions. Frank H. Laukien, Ph.D., Bruker’s President and... Read more
CHELMSFORD, Mass., June 05, 2017 (GLOBE NEWSWIRE) — Brooks Automation, Inc. (Nasdaq:BRKS) announced today that the company will present at the Jefferies Healthcare Conference at the Grand Hyatt Hotel, New York. Steve Schwartz, President and Chief Executive Officer and Lindon Robertson, Chief Financial Officer, will present on Thursday, June 8th at 10:00 a.m. Eastern Time. ... Read more
Kyoto, Japan and Québec, Canada – June 5, 2017. Shimadzu, one of the world’s fastest growing mass spectrometry companies, and Phytronix, world leader in high throughput analysis in mass spectrometry, announce today that they have signed an agreement to offer the industry’s first Triple Ion Source. Ideal for both screening and confirmation work, this new... Read more